CURRICULUM VITAE

________________________________________

Pang Xiaoyan,female

China Pharmaceutical University;

Pharmacokinetics, Pharmacognosy Ph.D

+86-138********, hgrpv3@r.postjobfree.com

________________________________________

Education

Sept. 2007-on Dept. of Tranditional Chinese Pharmacy, Majoring in Pharmacognosy, China Pharmaceutical University, Nanjing, China

Oct. 2008-Nov. 2010 Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, U.S.A.

Sept. 2004-June 2007 Dept. of Pharmacy, Majoring in Pharmacokinetics, China Pharmaceutical University, Nanjing, China

Sept. 2000-June 204 Dept. of Pharmacy, Majoring in Pharmacology, China Pharmaceutical University, Nanjing, China

________________________________________

Qualifications

• Basic pharmacokinetic experiment skills including in vivo of blood, urine, bile acid and other biofluid sample collection and in vitro of inhibition and induction experiment based on the microsome and hepatocyte

• Use of equipments such as Waters UPLC-UV, Agilent 1100/1200 series HPLC-UV, Agilent 6410 Triple Quadrupole Mass Spectrometer, Bruker HCT Ion Trap Mass Spectrometer

• Animal model skills, such as rat, mice, rabbit, toad, dog

• Basic molecular biology skills, such as western blot, real-time PCR, plasmid construction

• Cell culture skill

• Having a general knowledge of internet and making full use of the internet for academic studies and research

Research background

• Research of the quality control of multiple components in herbs

• Research of the influence of black cohosh on Cyp3a

• Research of the humanized mouse model of CYP3A7

• Research of the metabolomics of Tempol

• Research of the humanized mouse model of CYP2D6

• Research of the pregame X receptor related bowl inflammation

• The bioavailability research of diclofenac modified release capsule in the human being

• The bioavailability research of dimethylbiguanide retard tablet in the human being

• The bioavailability research of mycophenolate suspension in the human being

• The bioavailability research of amlodipine modified release capsule in the human being

• The determination of antofloxacin in rat articulation

• The research of the transport of antofloxacin in rat kidney

• The research of the interaction between nimodiping and erythromycin and their physiology pharmacokinetics

• Reveiw for the journal of Current Drug Metabolism

• Graduate from the course of Clinical Pharmacology held in National Institutes of Health

Publication

• Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ. Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica. 2011;41(2):112-2 (IF: 2.799)

• Pang X, Cheng J, Kim JH, Matsubara T, Krausz KW, Gonzalez FJ. Expression and Regulation of Human Fetal-specific CYP3A7 in Mice (In revision of Endocrinology) (IF: 4.752)

• Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010;335(1):32-41 (IF:4.093)

• Pang XY, Liu L, Zhang DM, Wang GJ, Xie L, Liu XD. The pharmacokinetics of antofloxacin in renally impaired rats. J Pharm Pharmacol. 2008;60(5):667-7 (IF:1.742)

• Pang XY, Xie L, Xu X, Liu HY, Liu L, Liu XD. The pharmacokinetics of antofloxacin in rats co-administered with non-steroidal anti-inflammatory drugs (NSAIDs) (Journal of China New Drug, 2007) (In Chinese)

• Liu L, Pang X, Zhang D, Xu X, Liu H, Liang Y, Xie L, Liu X. Determination of caderofloxacin lactate in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies. J Pharm Biomed Anal. 2007;45(5):799-80 (IF: 2.453)

• Sen Y, Pang X, Deng Y, Liu Li, Liang Y, Liu XD, Xie L, Wang GJ and Wang X. A sensitive and specific liquid chromatography mass spectrometry method for simultaneous determination of berberine, palmatine, coptisine, epiberberine and jatrorrhizine from Coptidis Rhizoma in rat plasma. Int J Mass Spectrom. 2007; 268(1): 30-37 (IF: 2.117)

Contact this candidate